The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer.
 
Antoine Hollebecque
Honoraria - Amgen; BMS; Eisai; Incyte; MSD Oncology; Relay Therapeutics; SERVIER
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Relay Therapeutics; Sanofi; Spectrum Pharmaceuticals (Inst); Taiho Oncology; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Pierre Fabre; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Takafumi Koyama
Honoraria - AstraZeneca; Chugai Pharma; Sysmex
Consulting or Advisory Role - Amgen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo RD Novare (Inst); Janssen (Inst); Lilly (Inst); Novartis (Inst); PACT Pharma (Inst); Pfizer (Inst); Takeda (Inst); Zymeworks (Inst)
 
Yutaka Fujiwara
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Johnson and Johnson; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chiome Bioscience; Daiichi Sankyo; Nippon Kayaku; Ono Pharmaceutical; Otsuka
Research Funding - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Incyte (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novocure (Inst); Shanghai Junshi BioSciences (Inst); Taiho Pharmaceutical (Inst)
 
Yonina Murciano-Goroff
Employment - Memorial Sloan Kettering Cancer Center (MSK has institutional financial interests relative to Elucida Oncology); Memorial Sloan-Kettering Cancer Center
Honoraria - Amgen; Virology Education
Consulting or Advisory Role - Abbvie; Revolution Medicines
Research Funding - Abbvie (Inst); Andrew Sabin Family Foundation; Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Conquer Cancer, the ASCO Foundation; Druckenmiller Center for Lung Cancer Research; Elucida Oncology (Inst); Endeavor BioMedicines (Inst); Hengrui Pharmaceutical (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo/Lilly (Inst); Luzsana Biotechnology (Inst); Mirati Therapeutics (Inst); National Cancer Institute; National Cancer Institute; National Institutes of Health (NIH)/National Cancer Institute (NCI); Squeri Grant for Drug Development; Taiho Oncology (Inst); The Society of Memorial Sloan Kettering
Patents, Royalties, Other Intellectual Property - Rutgers University Press; Wolters Kluwer
Travel, Accommodations, Expenses - AstraZeneca; Loxo Oncology/ Eli Lilly
Other Relationship - Endeavor Biomedicines
 
Philippe Cassier
Consulting or Advisory Role - Boehringer Ingelheim; Brenus Pharma; Bristol-Myers Squibb/Celgene; OSE Immunotherapeutics; Scenic Biotech; START
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); Alligator Bioscience (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Daiichi Sankyo/UCB Japan (Inst); Debiopharm Group (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Molecular Partners (Inst); Novartis (Inst); OSE Immunotherapeutics (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Roche/Genentech (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche
(OPTIONAL) Uncompensated Relationships - ReACT Therapeutics
 
Natraj Ammakkanavar
Stock and Other Ownership Interests - Autolus; Cardiff Oncology; Iovance Biotherapeutics; Kura Oncology; Shockwave Medical
Consulting or Advisory Role - AstraZeneca/MedImmune
Speakers' Bureau - Bristol-Myers Squibb/Celgene
Travel, Accommodations, Expenses - Loxo/Lilly
 
Dustin Deming
Consulting or Advisory Role - DoMoreDx; Foundation Medicine; Illumina; Inocras; Pfizer; Regeneron; Seagen; Taiho Oncology
Research Funding - AADi (Inst); Arcus Ventures (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Curegenix (Inst); Genentech (Inst); Ipsen; Lilly (Inst); Merck (Inst); Millennium (Inst); Natera (Inst); Promega (Inst); Revolution Medicines (Inst); Strata Oncology (Inst)
 
Carlos Gomez-Roca
Honoraria - PharmaMar; PSAD
Consulting or Advisory Role - Ellipses Pharma; Macomics
Research Funding - Amgen (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
(OPTIONAL) Uncompensated Relationships - ESMO; FITC; Oncodistinct
 
Sae-Won Han
Honoraria - IMBdx
Consulting or Advisory Role - AstraZeneca; Natera
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeyondBio (Inst); Cell Biotech (Inst); GC Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); Hengrui Pharmaceutical (Inst); IMBdx (Inst); Janssen (Inst); Jeil Pharmaceutical Co (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); MSD (Inst); Roche (Inst); Seagen (Inst); Turnstone Bio (Inst)
 
Mohamedtaki Tejani
Consulting or Advisory Role - Exelixis
Speakers' Bureau - Natera
Research Funding - Bayer (Inst)
 
Anthony El-Khoueiry
Honoraria - Agenus; AstraZeneca/MedImmune; Bristol-Myers Squibb; EISAI; Elevar Therapeutics; Exelixis; Merck; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; TERUMO
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Bristol-Myers Squibb; Eisai; Elevar Therapeutics; Exelixis; Genentech; Merck; Qurient; Roche; Senti Biosciences; SERVIER; TERUMO
Research Funding - Astex Pharmaceuticals; AstraZeneca; Auransa; Fulgent Genetics
Travel, Accommodations, Expenses - Affimed Therapeutics
 
Nagla Abdel Karim
Consulting or Advisory Role - Amgen; Bayer; Bristol Myers Squibb Foundation; G1 Therapeutics; Jazz Pharmaceuticals; Novocure; Sanofi/Regeneron
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb/Pfizer (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst)
 
Samantha Bowyer
No Relationships to Disclose
 
Victor Lin
Stock and Other Ownership Interests - Agilent; AstraZeneca; Bristol-Myers Squibb; Novartis
Research Funding - BeiGene; Merck; Mirati Therapeutics; Pfizer; Regeneron
 
Samuel McNeely
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Xintian You
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Aaron Chen
Employment - Loxo/Lilly; Sumitomo Pharma Oncology
Stock and Other Ownership Interests - Loxo/Lilly
Travel, Accommodations, Expenses - Loxo/Lilly
 
Aaron Fink
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Travel, Accommodations, Expenses - Lilly
 
Melinda Willard
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Travel, Accommodations, Expenses - Lilly
 
Yasutoshi Kuboki
Honoraria - Kyowa Kirin; Lilly Japan; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Incyte; Noile-Immune Biotech, Inc; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Carna Biosciences (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Genmab (Inst); Incyte (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Kyowa Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Chugai Pharma; Incyte